Study of VB-111 in Recurrent Glioblastoma

To evaluate the efficacy, safety and tolerability of VB-111 every 2 months combined with bevacizumab every 2 weeks in recurrent GBM patients compared to patients who receive bevacizumab every 2 weeks monotherapy

April 07, 2016